HSBC set a €56.00 ($63.64) price target on MorphoSys (ETR:MOR) in a report released on Tuesday. The brokerage currently has a sell rating on the stock.

Several other equities research analysts have also recently commented on MOR. Commerzbank set a €98.00 ($111.36) price objective on MorphoSys and gave the company a buy rating in a research report on Wednesday, April 18th. Deutsche Bank set a €95.00 ($107.95) price objective on MorphoSys and gave the company a buy rating in a research report on Tuesday, May 1st. Royal Bank of Canada set a €58.00 ($65.91) price objective on MorphoSys and gave the company a sell rating in a research report on Wednesday, May 2nd. Goldman Sachs Group set a €86.00 ($97.73) price objective on MorphoSys and gave the company a neutral rating in a research report on Thursday, May 3rd. Finally, Oddo Bhf set a €93.00 ($105.68) price objective on MorphoSys and gave the company a buy rating in a research report on Friday, May 4th. Two research analysts have rated the stock with a sell rating, four have issued a hold rating and four have assigned a buy rating to the stock. The company has a consensus rating of Hold and a consensus target price of €94.60 ($107.50).

MorphoSys stock opened at €98.80 ($112.27) on Tuesday. MorphoSys has a one year low of €49.63 ($56.40) and a one year high of €88.10 ($100.11).

About MorphoSys

MorphoSys AG, together with its subsidiaries, engages in the research, development, and optimization of therapeutic antibody drug candidates in partnership with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 drugs for the treatment of cancer, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation.

Read More: How Do You Make Money With Penny Stocks?

Analyst Recommendations for MorphoSys (ETR:MOR)

Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with MarketBeat.com's FREE daily email newsletter.